Literature DB >> 7727042

Inhibition of ras p21 membrane localization and modulation of protein kinase C isozyme expression during regression of chemical carcinogen-induced murine skin tumors by lovastatin.

S G Khan1, R Saxena, D R Bickers, H Mukhtar, R Agarwal.   

Abstract

We investigated the ras p21 membrane localization and the expression and activation of protein kinase C (PKC) isozymes in activated ras oncogene-containing tumors and assessed whether these events were related to tumor growth. We used 7,12-dimethylbenz[a]anthracene-initiated and 12-O-tetradecanoylphorbol-13-acetate-promoted SENCAR mouse skin tumors, which were shown to contain Ha-ras oncogene activated by point mutation at codon 61, as an in vivo model for these studies. Compared with levels in epidermis, highly elevated levels of membrane-bound Ha-ras p21 were observed in growing tumors, which also showed strong expression and membrane translocation of PKC zeta and beta II and weak expression of PCK alpha. However, when ras p21 membrane localization was blocked in vivo in growing tumors by lovastatin, opposite results were evident. Compared with saline-treated animals, in which tumor growth continued, lovastatin-treated animals had significantly inhibited tumor growth, which led to tumor regression with concomitant inhibition of Ha-ras p21 membrane localization. These regressing tumors from lovastatin-treated animals also showed a decrease in the expression and membrane translocation of PKC zeta and beta II but increased expression of PKC alpha. Taken together, our results indicate that ras p21 membrane localization and the expression and activation of PKC zeta, beta II, and alpha may be the critical events in the regulation of the growth of tumors that contain activated ras oncogenes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7727042     DOI: 10.1002/mc.2940120405

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  6 in total

Review 1.  How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.

Authors:  Ethan J Brock; Kyungmin Ji; John J Reiners; Raymond R Mattingly
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

2.  Low density lipoproteins and Lovastatin modulate the organ-specific transendothelial migration of primary and metastatic human colon adenocarcinoma cell lines in vitro.

Authors:  N Mehta; J Hordines; D Sykes; R J Doerr; S A Cohen
Journal:  Clin Exp Metastasis       Date:  1998-10       Impact factor: 5.150

3.  Elevated K-ras activity with cholestyramine and lovastatin, but not konjac mannan or niacin in lung--importance of mouse strain.

Authors:  Richard J Calvert; Shirley Tepper; Wafa Kammouni; Lucy M Anderson; David Kritchevsky
Journal:  Biochem Pharmacol       Date:  2006-09-03       Impact factor: 5.858

4.  Primarily screening and analyzing ESTs differentially expressed in rats' primary liver cancer.

Authors:  Dandan Liu; Lijuan Zhi; Mingxia Ma; Dan Qiao; Meijuan Wang; Yawei Wang; Baijie Jin; Anqi Li; Guting Liu; Yiqing Zhang; Yanyan Song; Hongxu Zhang
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087

5.  Statin use and risk of basal cell carcinoma.

Authors:  Maryam M Asgari; Jean Tang; Ervin H Epstein; Mary-Margaret Chren; E Margaret Warton; Charles P Quesenberry; Alan S Go; Gary D Friedman
Journal:  J Am Acad Dermatol       Date:  2009-05-21       Impact factor: 11.527

6.  Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats.

Authors:  T Narisawa; M Morotomi; Y Fukaura; M Hasebe; M Ito; R Aizawa
Journal:  Jpn J Cancer Res       Date:  1996-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.